Oncoinvent ASA: Grant of share options to new Chief Medical Officer
Oslo, Norway, 28 October 2026: Oncoinvent has granted the new Chief Medical Officer (CMO) Dr Zuzana Jirakova Trnkova 20,000 share options in the Company under the Company's long term incentive program, each with a strike price of NOK 67.35, equal to the volume weighted average share price the last day before the grant. See the attached form. Following the grant of the 20,000 share options referred to above, Zuzana Jirakova Trnkova holds 20,000 options in the Company.
Each option, when exercised, will give the right to acquire one share in the Company. The options are granted without consideration. No Options shall vest during the first 12 months following the date of the Grant Letter, 13/48 of the Options shall vest in the 13th month, and the remaining Options shall thereafter vest in equal monthly instalments of 1/48 (as long as the option holder is still employed). Options that have not been exercised will lapse 7 years after the date of grant.
The board considers an option program as an important element in attracting and retaining employees to foster long-term success. The Board considers the option program terms and allocation to be at the market for comparable peers.
PDMR Zuzana Jiráková Trnková.pdf (https://mb.cision.com/Public/15728/4416272/84908ae2b0764c84.pdf)
This information is subject to the disclosure requirements pursuant to Regulation (EU) 596/2014 (MAR) Article 19 and Section 5-12 of the Norwegian Securities Trading Act.
For further information, please contact:
Oystein Soug, Chief Executive Officer Email: IR@oncoinvent.com (soug@oncoinvent.com)
This information is published in accordance with article 19 of the EU Market Abuse Regulation (MAR).
About Oncoinvent
Oncoinvent is developing Radspherin[®], a receptor-independent alpha radiation therapy that leverages the unique anatomy of the abdominal cavity to destroy residual micrometastases using a single, highly localized dose of alpha radiation. The initial clinical focus is treatment of ovarian and colorectal cancer patients after surgical removal of the primary tumor and visible metastases in the peritoneum, the thin membrane lining the abdominal cavity and covering the abdominal organs.
This radiopharmaceutical is designed to prevent or delay recurrence in the peritoneal cavity, keeping patients disease-free for longer than the current standard of care and thereby also impacting overall survival. It is broadly applicable to any cancer that spreads to the peritoneum, e.g. ovarian, colorectal, and gastric cancers. Radspherin[®] stands out for its simplicity, excellent safety profile, and seamless integration into existing surgical workflows. Oncoinvent's product is easy to use, avoids systemic delivery and significant toxicity. It is also differentiated in being simple to manufacture, scalable, and supply de-risked.
Data from two trials in ovarian (phase 1) and colorectal (phase 1/2a) cancers are highly promising, showing an excellent safety profile and meaningful signals of efficacy. Interim data from an ongoing, randomized, controlled phase 2 ovarian cancer trial is expected in 2H2026 (safety) and 1H2027 (early efficacy). With cost-effective manufacturing, blockbuster potential, active pharma partnership momentum, plus strong endorsements from leading experts, Oncoinvent is built for scale and commercial success, and is set to become the new standard for post-surgical cancer care. The Company was founded by the originators of Algeta and Xofigo (acquired by Bayer).